Skip to main content

Table 2 Baseline demographic and clinical characteristics of the NUCs discontinuation patients treated by lamivudine, adefovir, entecavir, and telbivudine

From: Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative

Characteristic LAM ADV ETV LDT
Number. (%) 15 (22.7) 42 (63.6) 7 (10.6) 2 (3.0)
Age (Mean ±SD) - yr 34.1±13.0 35.3±10.6 36.1±14.0 33.5±10.6
  <29 - no. 4 9 2 1
  30-39 - no. 8 24 3 0
  >39 - no. 3 9 2 1
Man - no. (%) 14 (93.3) 30 (71.4) 4 (57.1) 2 (100)
ALT [Median (IQR)] - ULN 2.6 (1.2-3.5) 2.5 (1.3-6.6) 4.7 (2.7-14.0) 9.5 (3.9, 15.0)
HBV DNA - log10 IU/mL 6.3±1.6 5.3±1.3 5.5±0.8 7.0±2.2
HBsAg loss - no. (%) 2 (100) 0 0 0
  1. LAM, lamivudine; ADV, adefovir; ETV, entecavir; LDT, telbivudine.